Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sharon Nahill is active.

Publication


Featured researches published by Sharon Nahill.


Transplantation | 2009

Polyclonal Rabbit Antithymocyte Globulin Exhibits Consistent Immunosuppressive Capabilities Beyond Cell Depletion

Gina Lacorcia; Mark Swistak; Carla Lawendowski; Su Duan; Tim Weeden; Sharon Nahill; John M. Williams; John Lyle Dzuris

Background. Polyclonal antithymocyte globulins (ATGs) are used clinically to prevent and treat acute allograft rejection and are believed to modulate the immune response primarily by depleting T cells. However, nondepleting mechanisms may also be important mediators of graft survival. In the present study, 14 lots of thymoglobulin (rabbit ATG) were analyzed and compared for nondepletive immunomodulatory activities in vitro. Methods. Coincubation of human peripheral blood mononuclear cells with thymoglobulin induces CD4+CD25highFoxp3+ regulatory T cells, which were evaluated for consistent ability to suppress T-cell activation in mixed lymphocyte reactions. The consistency of CD2, CD3, CD11a, and CD45 antigen specificities in thymoglobulin was determined using flow cytometry to measure inhibition of fluorescent monoclonal antibody binding to Jurkat T cells. A transwell chemotaxis assay was established and used to evaluate ATG-mediated inhibition of stromal cell-derived factor (SDF)-1α-driven Jurkat T-cell migration. Results. Physiologic levels of thymoglobulin produced nondepletive immunomodulatory activities, which were consistent from batch to batch. All lots of thymoglobulin induced functionally immunosuppressive regulatory T cells and inhibited monoclonal antibody binding to key T-cell surface antigens. In addition, these studies provide the first demonstration that thymoglobulin effectively inhibits CXCR4/SDF-1α-driven T-cell chemotaxis. Conclusions. This novel, systematic in vitro analysis of 14 different manufactured lots of thymoglobulin demonstrates the overall consistency of this product and provides further insights into nondepletive mechanisms by which thymoglobulin may generate durable immunoregulation and allograft survival.


Transplantation | 2007

Selected Mechanistic Studies and Future Directions for Thymoglobulin

Melanie Ruzek; John Lyle Dzuris; Lan Gao; Russell Bigelow; James Waire; Abraham Scaria; Sharon Nahill; John M. Williams

A murine anti-thymocyte globulin, which was made in rabbits using the same manufacturing protocol used in production of Thymoglobulin (Genzyme Transplant, Cambridge, MA), was used to explore the biology and mechanism of action of Thymoglobulin. These preclinical studies suggest that determining optimal dosing and timing of Thymoglobulin can contribute to maximizing protection against allograft rejection. The murine anti-thymocyte globulin has a demonstrated ability to induce cells in vitro with a T-regulatory phenotype and was also shown to be effective in vivo in protecting mice against acute GVHD and in reversing overt diabetes in nonobese diabetic mice. The mechanistic rationale for Thymoglobulin as a therapeutic agent for the treatment of systemic lupus erythematosus, multiple myeloma, and myelodysplastic syndrome was also explored.


Bioorganic & Medicinal Chemistry Letters | 2003

Ureas of 5-aminopyrazole and 2-aminothiazole inhibit growth of gram-positive bacteria.

John L. Kane; Bradford Hirth; Beirong Liang; Brian B. Gourlie; Sharon Nahill; Gary Barsomian


Blood | 2007

Characterization of in vitro antimurine thymocyte globulin–induced regulatory T cells that inhibit graft-versus-host disease in vivo

Melanie Ruzek; James Waire; Deborah A. Hopkins; Gina Lacorcia; Jennifer Sullivan; Bruce L. Roberts; Susan M. Richards; Sharon Nahill; John M. Williams; Abraham Scaria; John Lyle Dzuris; Srinivas Shankara; Richard D. Garman


International Immunology | 2007

Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3+ regulatory T cells

Denise T. Chung; Thomas Korn; Julie Richard; Melanie Ruzek; Adam P. Kohm; Stephen D. Miller; Sharon Nahill; Mohamed Oukka


Archive | 2001

Modulators of TNF-α signaling

Scott F. Sneddon; John L. Kane; Bradford Hirth; Frederic Vinick; Shuang Qiao; Sharon Nahill; John M. Williams; Hans-Peter Biemann


Clinical Immunology | 2007

Anti-Thymocyte Globulin Prevents Autoimmune Encephalomyelitis by Expanding Myelin Antigen Specific Foxp3+ Regulatory T Cells

Denise Chung; Thomas Korn; Julie Richard; Adam P. Kohm; Melanie Ruzek; Mohamed Oukka; Stephen D. Miller; Sharon Nahill; Vijay K. Kuchroo


Archive | 2010

regulatory T cells that inhibit graft-versus-host disease in vivo Characterization of in vitro antimurine thymocyte globulininduced

Srinivas Shankara; Richard D. Garman; Susan Richards; Sharon Nahill; John M. Williams; Abraham Scaria; John Lyle Dzuris; Melanie Ruzek; James Waire; Deborah A. Hopkins; Jennifer Sullivan; Laura L. Bruce


Archive | 2001

Modulatoren des tnf-alpha-signalweges

Scott F. Sneddon; John L. Kane; Bradford Hirth; Fred Vinick; Shuang Qiao; Sharon Nahill; M Williams John; Biemann Hans-Peter


Archive | 2001

Modulateurs de marquage du tnf-alpha

John M. Williams; Hans-Peter Biemann; Andrew Janjigian; Scott F. Sneddon; John L. Kane; Bradford Hirth; Fred Vinick; Shuang Qiao; Sharon Nahill

Collaboration


Dive into the Sharon Nahill's collaboration.

Top Co-Authors

Avatar

John M. Williams

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Adam P. Kohm

Northwestern University

View shared research outputs
Researchain Logo
Decentralizing Knowledge